The U.S. Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have issued a Fourth Temporary Extension of the COVID-19 Telemedicine Flexibilities for the Prescription of Controlled Medications, allowing providers to remotely prescribe Schedule II-V controlled medications indefinitely, following at least one initial in-person medical evaluation. "This permits the practitioner to remotely prescribe controlled substances to that patient indefinitely, regardles

ٍRIYADH, SAUDI ARABIA, December 31, 2025 / EINPresswire.com / -- King Faisal Specialist Hospital & Research Centre continues to advance pediatric care through specialized programs dedicated to solid tumors and non-malignant blood disorders, supported by multidisciplinary clinical teams and long-term follow-up models. The Pediatric Solid Tumor Program receives approximately 200 newly diagnosed cases each year, including brain tumors, bone and soft tissue sarcomas, renal tumors, hepatic tumors, re

AbbVie began 2025 with a T cell engager deal in China, and it’s ending the year with another one. The Chicago-area pharmaceutical giant is going to Zelgen Biopharmaceuticals for a clinical-stage T cell engager called ZG006, or alveltamig, according to a Shanghai Stock Exchange filing and local financial information websites. AbbVie will pay $100 million upfront, as much as $60 million in licensing options payments and up to $1.075 billion in biobucks. The deal adds to a significant ramp-up in Ch

New Delhi: With rising safety concerns over syrup formulations, the Union Health Ministry is looking to revoke exemptions for the category and ‘remove’ it from the OTC drug list . In a notification dated December 29, the ministry stated “Syrup” will be omitted from the “Class of Drugs” under the Schedule K, of the Drugs Rules, 1945. The decision comes months after the deaths of at least 24 children in Madhya Pradesh, who consumed an DEG adulterated brand: Corlif cough syrup, and the death of a c

Vanda Pharmaceuticals won FDA approval for what it says is the first new medicine for motion sickness in more than four decades. The oral drug, called Nereus, will be launched in the coming months, Vanda said in a Tuesday press release . The company said Nereus, also known as tradipitant, “consistently demonstrated significant reductions in vomiting” in pivotal trials. In a Phase 3 study conducted on boats called Motion Syros, vomiting incidence was 18.3% to 19.5% with Nereus compared to 44.3% w

NY, NY, UNITED STATES, December 31, 2025 / EINPresswire.com / -- In the rapidly evolving landscape of modern biotechnology, the precision of molecular tools determines the speed of medical breakthroughs. As a Global Leading Biotinylated Peptide Synthesis specialist, Alpha Lifetech Inc. is at the forefront of this revolution, providing the critical building blocks that enable researchers to decode complex biological interactions. From the development of next-generation cancer therapeutics to the

Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company release shared Wednesday, a day after the original PDUFA date. Cushing’s syndrome is driven by excess levels of the hormone cortisol, leading to high blood pressure, high blood sugar and obesity. The FDA said in its complete response letter it could not reach a positive opinio

Experts highlight “nociplastic pain,” a newly defined pain mechanism changing how chronic pain is understood and treated Many chronic pain patients suffer not from damage, but from a sensitized nervous system. Recognizing nociplastic pain changes how we diagnose, explain, and treat pain.” — — Dr. Gautam Das KOLKATA, WEST BENGAL, INDIA, December 31, 2025 / EINPresswire.com / -- Millions of people live with chronic pain that persists despite scans, injections, and even surgery. For many, test resu

UCSD and the Department of Veterans Affairs Collaboration CARLSBAD, CA, UNITED STATES, December 31, 2025 / EINPresswire.com / -- AVACEN Medical announced today that Dr. Francisco Cidral, ND, PhD’s narrated review of the AVACEN Fibromyalgia Pilot Study is now available online . Detailed AVACEN study results can also be found at ClinicalTrials.gov , a service of the U.S. National Institutes of Health. ClinicalTrials.gov is a web-based resource that provides patients, their family members, health c

The Customs Tariff Commission of the State Council of China has announced that beginning in 2026, the country will start to lower import duties on certain products. Levies will be lowered on resource-based commodities, including black ⁠powder for ‌lithium-ion batteries, as well as certain medical products, including artificial blood vessels and diagnostic kits for certain infectious ‌disease. For a total of 925 products, provisional import tariff rates will be lower than most-favoured-nation ⁠ra